摘要
目的:探讨慢性心力衰竭(chronic heart failure,CHF)病人给予新活素(冻干重组人脑利钠肽)治疗对心功能、高敏C反应蛋白及血浆NT-proBNP的影响,并评价其临床应用价值及安全性。方法:选取CHF病人61例,随机分为2组,均接受常规治疗,其中治疗组31例,给予新活素治疗;对照组30例,给予硝酸甘油治疗。观察两组治疗前后生命体征、呼吸困难程度、C反应蛋白、射血分数及血浆NT-proBNP生化指标的变化。结果:治疗组总有率高于对照组,射血分数、C反应蛋白、血浆NT-proBNP均好于对照组(P<0.05);LVDD均无明显变化,无显著性差异(P>0.05)。结论:新活素可减轻CHF病人呼吸困难、改善全身状况、提高射血分数、降低血浆NT-proBNP,并具有良好的安全性。
Objective：To evaluate the efficacy and safety of B-type natriuretic peptide in the treatment of chronic heart failure （CHF）through objective values of NT-proBNP,C-reaction protein on plasma. Methods： Randomized, open, control clinical trial was conducted in 61 patients with CHF. 31 of the patients were treated with B-type natriuretic peptide in the trial group, and 30 were treated with nitroglycerin n the control group. Vital signs, dyspnea, eject fraction （ EF）, NT-proBNP and C-reaction protein in blood biochemical index before and after drug administration were observed. Results：There were significant diferences in the increase of the EF, in the decrease of NT-proBNP and C-reaction protein between the trial group and control group, but no significant diferences were found in LVDD. Side effects were found in 2 patients of the trial group and 5 patients of the control group. Conclusion ： Levosimendan is effective in treating CHF and it can relieve dyspnea, improve the general condition,increase EF,decrease NT-proBNP and C-reaction protein.
出处
《内蒙古医科大学学报》
2013年第4期286-289,共4页
Journal of Inner Mongolia Medical University
基金
国家自然科学基金(81260269)
